Take part in research

In this section, you will find a list of all clinical research studies currently being supported by our department.

Research studies by category (A-Z)

Anxiety and Depression

The GLAD Study is a project set up to explore risk factors in individuals who have experienced depression and/or anxiety, including those with a diagnosis of bipolar disorder, OCD, or related disorders, at any time in their lives.

It aims to better understand depression and anxiety in order to find and develop more effective treatments. The GLAD Study is also part of the NIHR BioResource, which is a library of information about people’s health aiming to support research in both physical and mental health.

To take part in this study, people must:

  • Have experienced symptoms of anxiety and/or depression during your life
  • Be aged 16 and above
  • Live in the UK

The GLAD Study enrolment process consists of four steps:

  1. Register on the website www.gladstudy.org.uk and read the Information Sheet
  2. Provide consent (please put AWP as where you heard about the study)
  3. Complete a questionnaire
  4. Provide a saliva sample

AWP Research and Development contacts:

Alexandra Young (alexandra.young6@nhs.net)

 

This study will close on the 30th November 2024

GLAD logo.jpg

Clinical depression can impact an individual’s mood and motivation to pursue goals and affects how rewarding they find them. Current first-line treatments, such as psychological therapies and antidepressants, haven’t always proven effective for a good proportion of people who might have Treatment Resistant Depression (TRD).

PAX-D study aims to use an already existing drug called pramipexole (which is currently being used for Parkinson's disease) that could prove effective treatment for TRD by impacting factors such as mood and motivation. 

During the trial, one group of people will be taking pramipexole and the other group will be taking a placebo; a tablet that looks like pramipexole, but has no effect. At the end of the trial, we will compare the information collected on people taking pramipexole with that from people taking placebo.

To take part in this study, people must:

  • Be aged 18 or above (male or female)
  • Have a diagnosis of major depression (DSM-V)
  • Be currently taking an antidepressant medication and willing to continue 
  • Have lacked response to at least two antidepressants at therapeutic doses

Further information: 

PAX-D study website: https://paxd.web.ox.ac.uk/

AWP Research and Development contacts:

Alexandra Young (alexandra.young6@nhs.net

Mashal Asif (mashal.asif1@nhs.net

 

This study will close on the 31st May 2024

 

PAX-D logo.jpg
 

Autistic Spectrum

ADEPT-2 is a Randomised Control Trial (RCT) for autistic adults, comparing Guided Self-Help with NHS support for depression.

Depression is a common mental health issue, related to lower quality of life. Research indicates that autistic people are more likely to experience depression than non-autistic people. 

Effective treatment for depression includes a talking therapy called low intensity Cognitive Behavioural Therapy (CBT). This form of low intensity therapy is based on supporting the person receiving therapy to work through evidence-based information. This is called Guided Self-Help which has been shown to be useful in non-autistic adults, but it is not known whether it would also be useful for autistic adults.

The main goal of the ADEPT-2 study is to find out whether Guided Self-Help is helpful in reducing depression experienced by autistic adults. 

The ADEPT-2 study also aims to determine whether Guided Self-Help would have a good cost-benefit for the NHS. In addition, the ADEPT-2 study aims to find out whether Guided Self-Help received by an autistic adult has impact on their family carers or supporters. 

To take part in this study, people must:

  • Be aged 18 and over
  • Have received a diagnosis of autism spectrum disorder from a healthcare professional(s)
  • Experience low mood or depression
  • Be able to complete forms with questions either online or on paper
  • Be able to give informed consent to take part 

Further information:

If you decide to take part in the study, you will be randomly selected to receive either Guided Self-Help or NHS support for depression. 

Guided Self-Help involves using a booklet, as well as attending 9 individual meetings with a coach to support use of the booklet. These meetings will be online. If you prefer to meet in person, the study team would be happy to discuss whether that would be possible.   

NHS support for depression might include talking therapy, medication, self-coping strategies, and access to support groups. 

The study will last for 52 weeks. Taking part will involve completing questionnaires at the start of the study, as well as 16 weeks, 32 weeks and 52 weeks later. You will be able to claim a £10 gift voucher for completing every set of questionnaires in the study. There will also be the option to be interviewed about your experience of the study at the end of the study. 

Further information about the ADEPT-2 study can be found here.

ADEPT-2 study team contact:

If you wish to discuss the ADEPT-2 study or reasonable adjustments for taking part in the study, you can contact the ADEPT-2 study team directly by telephone (07855 973171) or email (adept-takepart@bristol.ac.uk)

AWP Research and Development contact:

awp.adept-2@nhs.net

 

This study will close on the 29th February 2024

 

ADEPT-2 logo.jpg

Bipolar and Psychosis 

The Integrated Bipolar Parenting Intervention Trial (IBPI) team based at Lancaster University and Lancashire and South Cumbria NHS Foundation Trust are trying to find out whether providing online parenting support for parents with bipolar disorder (BD) helps parents to feel less stressed, have more confidence and experience fewer mood problems. The trial also aims to see whether use of the support leads their children to having fewer behavioural and emotional problems.

To take part in this trial, people must: 

  • Have a diagnosis of Bipolar Disorder (BD)
  • Have a child aged 4-10 years old (with whom you have at least 10 hours of contact with a week)
  • Have access to the internet

Further Information:

The Integrated Bipolar Parenting Intervention (IBPI) is an online tool that combines parenting support with helpful strategies for managing bipolar, and can be accessed on computers, mobile phones or tablets. 

Individuals will be randomly allocated (50/50 chance) to receive the intervention or to receive what would be considered their usual care. Those that are allocated to receive usual care will be able to access the IBPI tool once they have completed the trial (after 48 weeks). 

All activities related to the IBPI Trial will be done remotely / online. 

If you are interested in finding out more and registering your interest, please visit: Bipolar-Parenting-Study | Lancaster University

IBPI Trial contact:

Telephone: 07507 856960
Email: ibpi@lancaster.ac.uk 
Website: www.lancs.ac.uk/spectrum/IBPI 

 

This study will close on the 31st January 2025

 

Logo, company nameDescription automatically generated

The National Centre for Mental Health (NCMH) are researching the causes of mental health problems. Researchers are looking to gather information about people’s environment, lifestyle, and biology (including genes). Using this information, researchers hope to better understand why people experience mental health issues and how to develop better treatments. 

To take part in this study, people must:

  • Be 18 years old or over
  • Have a diagnosis of psychosis, schizophrenia, bipolar affective disorder, or depression
  • Understand spoken or written English

Further information:

Taking part in this study would involve meeting a member of the AWP Research & Development team either in person or by telephone or video call. 

At this meeting, you would have the opportunity to ask questions about the study and have time to think about taking part.

If you consent to taking part, the next step requires the completion of a questionnaire with a researcher. This would involve personal questions about your environment, lifestyle, and health, including mental health. 

There would be an expectation to provide a blood sample taken from the arm.

There would be further questions to complete within a week of the assessment, taking around 30 minutes.

NCMH are offering a £25 gift voucher to participants as a thank you.

AWP Research and Development Contacts:

awp.ncmh@nhs.net

 

This study will close on the 29th February 2024

Psychotic disorders, including Schizophrenia affect many people. Evidence suggests that inflammation in the body may have a role in the development of psychotic symptoms and may make it difficult for people to get better despite taking anti-psychotic medication.

This study aims to examine the role of inflammation in psychosis. To test this, participants who have inflammation will be randomly allocated to receive either the study intervention which is a single Intravenous (IV) infusion of an anti-inflammatory medication which already exists called Tocilizumab or the study control, which is a single IV infusion of normal saline solution which will have no effect on levels of inflammation in the body. Participants will not know whether they have received the intervention or control.

The study will examine if reducing levels of inflammation using the medication can help reduce symptoms of psychosis.

This study will support us to understand whether inflammation has a role in causing psychosis and if in the future, anti-inflammatory drugs may help in the treatment of psychosis for some people.

To take part in this study, people must be:

  • Aged 18 - 40
  • Diagnosis of psychosis (Schizophrenia or related psychoses) and within three years of first diagnosis of psychotic disorder.
  • If on anti-psychotic medication, stable on treatment regime with no changes in the past 2 weeks.
  • Able to give informed consent, including consent to share information with your General Practitioner (GP) and to access secondary care and GP records.
  • Able to understand written and spoken English.
  • Able to consent to providing blood samples.
  • Willing to abstain from strenuous exercise for 72 hours before the assessment visits.
  • Not pregnant (confirmed by urine pregnancy test) or breast-feeding.
  • Have a Body mass index (BMI) < 35 (i.e., WHO obesity class II or below).
  • There are other study eligibility criteria, which includes a number of co-morbid physical and mental health conditions and history, which are not listed above. If you have any questions about the criteria specifically, please email awp.pimsresearchtrial@nhs.net.

Further information: 

Service users interested in taking part in the trial will be invited to attend a couple of in person appointments. During these appointments, service users will be provided with information about the study, be asked to provide informed consent and will be assessed for suitability for the trial. During these appointments, service users will complete some questionnaires, cognitive tests and provide blood samples. (There is also an optional MRI scan).

Participants with evidence of inflammation (measured by a blood test), will also be asked to complete some further blood tests and a chest X-Ray before being randomised into the study.

Participants with no evidence of inflammation, will stop taking part in the study at this stage.

Participants who have of psychosis and inflammation who are eligible to take part in the trial, will be randomised to receive either a single dose of Tocilizumab or normal saline solution, which are administered via intravenous (IV) infusion.

The study also involves some follow up appointments at 7 days, 14 days and 28 days after receiving the infusion. During these appointments, participants are asked to complete further blood tests, questionnaires and cognitive tests (there is also an optional MRI scan).

Participation in the trial will end at 42 days after receiving the infusion when participants are contacted by the study team for a final check in.  

Eligible service users who take part in the trial will be offered payment after completing different stages of the study, as a thank you for their time.

Participants can also claim reimbursement for travel expenses.

 

The PIMS Trial study website: Psychosis Immune Mechanism Stratified Medicine Study - University of Birmingham

 

AWP Research and Development contacts:

If you wish to discuss the PIMS Trial or are interested in taking part in the study, you can contact the PIMS study team by email awp.pimsresearchtrial@nhs.net

 

This study will close on the 15th February 2025.

The University of Manchester are conducting a research study to understand staff and service user views about using digital devices, such as a smartphone or wearable device, to help manage mental health. 

The study team would like to understand service user opinions of this topic, as well as how people use digital devices. 

The study will aim to survey at least 300 people with lived-experience of psychosis. The study team would like those taking part in the survey to have a wide range of experience using technology. This includes people that already use a smartphone or wearable device, and those that do not. 

To take part in this study, people must:

  • Be aged 18 or above
  • Have a diagnosis or have treatment for psychosis, schizophrenia, or unusual distressing experiences (e.g. hearing voices or having usual beliefs)
  • Be able to understand and speak English

Further information: 

You will be asked some questions about your age, mental health and use of mental health services to confirm you can take part in the study. 

If you are able to take part, you will be asked to complete a survey; either online or using a paper copy. This survey will ask about your views of digital devices, as well as how these can be used in mental healthcare. 

The survey should take 20-30 minutes to complete. Survey responses are anonymous and there will be no way to identify the people that take part. 

By taking part in this survey, you service users are eligible to be entered into a prize draw to win £50 (as vouchers, cash, or bank payment). 

To read the participant information sheet and take part in the study, please click here

AWP Research and Development contacts:

Harry Walker (harry.walker@nhs.net)

 

This study closes on the 1st May 2024
 

The STOP trial aims to investigate the use of a new treatment for the symptoms of paranoia. The treatment uses a mobile phone App aimed at reducing cognitive bias, meaning the way the brain simplifies information through the filters of personal experience. The trial will test whether the mobile phone App can help replace harmful and distressing paranoid thoughts with better alternatives. 

To take part in this study, people must:

  • Be age 18 or above
  • Have clinically significant paranoid and persecutory symptoms that have continued for at least a month, regardless of diagnosis
  • Have been stable on psychotropic medication for a minimum of 3 months
  • Have no major physical illness or substance misuse issues (alcohol or drugs)
  • Have an understanding of written and spoken English
  • Have capacity to consent to take part in the trial

Further information:

You will be asked to use a mobile phone App once per week for either 6 or 12 weeks. This App can be downloaded onto your own smartphone or a smartphone that can be provided for the trial period.

You will be asked to complete an initial assessment with a researcher at the University of Bath. Following this assessment, the researcher will phone you either weekly or fortnightly for a short conversation. There will be follow-up assessments at 6, 12, 18 and 24 weeks after starting the trial. You can claim £20 for completing each follow-up assessment and a final assessment. 

Taking part in this trial does not affect access to your current treatment. Taking part in this trial is voluntary and anyone can withdraw at any point. 

More information about the STOP trial can be found here

AWP Research and Development contacts:

Darren French (d.french4@nhs.net)

David Rudall (d.rudall@nhs.net)

 

This study will close on the 30th June 2024

 

STOP logo.jpg
 

The University of Oxford Study team are interested in better understanding why people might get angry or become aggressive to better support people and improve treatments to reduce violence. 

To take part in this study, people must: 

  • Be aged 16 or older
  • Identify as male
  • Are in contact with mental health services
  • Have been given a diagnosis of psychosis

Individuals do not need to have had experiences with anger, aggression or violence to take part in this study – all experiences are equally helpful. 

Further Information:

Individuals will be asked to complete a number of questionnaires supported by someone from the Research and Development delivery team, which should take around an hour to complete. These can be completed in person, online, on the phone, or via video call depending on your preference. 

The questionnaires will ask for: demographic information, experiences of feeling angry, how individuals cope with anger, individual beliefs and feelings towards aggression and thoughts they may have about other people. Participants will be offered £15 as a thank you for taking part.

A small group of about 100 people will be asked to complete a small portion of the questionnaires one week later. This is optional.

AWP Research and Development contacts:

Monalisa Bora-White (Monalisa.Bora-White@nhs.net

 

This study will close on the 29th May 2024
 

Complex Emotional Needs

Some people in contact with mental health services experience emotional distress that is linked to long-standing difficulties in relationships with other people. This can affect their ability to form and maintain healthy relationships with other people. This can also affect mood and ability to manage difficult feelings. 

Existing psychological approaches are helpful to people with complex emotional needs, but these can be long-term and delivered in groups. There can be long waiting lists for these groups and people can find it difficult to attend due to different reasons.  

Structured Psychological Support (or SPS) is a short-term and less intense type of support for people with complex emotional needs. This study aims to find out if Structured Psychological Support (SPS) is effective. 

In the SPS study, people taking part will be divided at random into two groups. 

One group of people taking part will receive the SPS intervention. This intervention includes six to ten sessions of psychological support. These sessions will be delivered by a trained professional on a one-to-one basis. The sessions will focus on personal difficulties, as well as techniques to improve mental health and functioning. 

The other group will receive treatment-as-usual, meaning that the available support is no different to that normally available to you. However, if you do not already have a personal safety or crisis plan, you will be invited to create one in an appointment with a trained mental health professional. 

To take part in the SPS study, people must:

  • Be aged 18 or over
  • Be suggested for the study by a mental health professional who has assessed you as having complex emotional needs
  • Not be receiving or on a waiting list to receive treatment for complex emotional needs
  • Not have a psychotic mental health condition, such as schizophrenia
  • Not have an organic mental health condition, such as dementia 
  • Be willing and able to provide informed consent to take part in the study

Further information:   

Before the SPS study starts, you will be asked to a face-to-face appointment to give your consent to take part, and complete a brief questionnaire to check you can take part. If you are able to take part, you will be asked to complete a number of questionnaires. 

These questionnaires ask about your mental and physical health, the way you feel about life and health, and your use of health services. The SPS study team would also like to ask about your social life and activity in the community. You will be offered a £10 voucher for completing the questionnaires.

After the start of the study, a researcher will check in with you at 3 months and 9 months by telephone call. Following 6 and 12 months into the study, you will be asked to attend face-to-face appointments, where you will be asked to repeat the same questionnaires as the start of the study. If you are unable to make a face-to-face appointment, then an online meeting would also be an option. Each time you complete the questionnaire you will offered a £20 voucher.

At the end of the study, the SPS study team might ask you to an interview about your experiences of the study. This interview is optional. 

The SPS study is being coordinated by Imperial College London over seven NHS Trusts.

AWP Research and Development contact:

awp.sps.trial@nhs.net 
 

This study will close on the 8th February 2024

Dementia

The MySmile Study is a Randomised Control Trial (RCT) for adults with Alzheimer’s disease, looking at whether reducing periodontal infection (gum disease) slows the progression of cognitive impairment. Periodontal infection is mainly caused by inflammation of gums and surrounding bone. 

The MySmile research group and others have found links between Alzheimer’s and gum disease. Gum disease occurs when certain bacteria thrive under the gum line causing inflammation and bleeding. There is good evidence these bacteria pass into the bloodstream and speed up, or cause development of other diseases (such as diabetes and heart disease).

The study will compare two groups of patients who have both early Alzheimer’s and gum disease. One group will continue to look after their teeth and attend their own dental practice as usual. The other group will receive a personalised mouth care plan with all treatment provided at Bristol Dental Hospital or an accredited General Dental Practice.

The study will last 18 months. Taking part will involve completing a number memory tests, having dental assessments, and providing saliva and blood samples at different time points over 18 months.

To take part in the study, people must:

  • Be aged 60 and over
  • Have a diagnosis of Alzheimer’s Disease of Mild Cognitive Impairment 
  • Be interested in improving your oral (gum) health

MySmile study team contact:

If you wish to discuss taking part in the MySmile study, you can contact the MySmile study team directly by telephone (07773 579130) or email (Nikki.Hellin@bristol.ac.uk)

AWP Research and Development contact:

Monalisa Bora-White (monalisa.bora-white@nhs.net

 

This study closes on the 31st January 2024

 

Research has revealed the prevalence of anxiety and depression in carers of people with dementia is higher than the general population. Care is usually offered by NHS psychological services, but this poses potential barriers to carers, such as mobility issues, lack of respite care access or long waiting lists. 

Online treatments are a way to address this issue as they can be delivered remotely in the person’s own time. iACT4CARERS uses an online Acceptance and Commitment Therapy (ACT); a psychotherapy aiming to improve mood and quality of life. ACT does not aim to change thoughts and feelings, but reduce avoidance of them and enhance personally meaningful behaviour. 

iACT4CARERS aims to understand the effectiveness of ACT in reducing symptoms of anxiety in carers.

To take part in this study, people must:

  • Be over the age of 18 years old
  • Be caring for a family member diagnosed with dementia
  • Be experiencing anxieties or worries
  • Have access to a smartphone, tablet or computer
  • Have access to the internet

Further information:

The iACT4CARERS trial is a 12-week self-directed therapy. iACT4CARERS can be accessed from participant’s own home using a smartphone, tablet or computer.

Participants will be asked to complete eight, 40-60 minute, online sessions over this time and provide your reflections after each session.  A trial therapist will support participants over this time, providing tailored written feedback after each session and two optional 30-minute phone calls.

Before enrolling in the study, participants will be asked to complete baseline questionnaires about themselves and their thoughts and feelings regarding their caregiving role. Participants will be asked to complete these again at 12-weeks and 24-weeks to assess the impact of ACT.

By completing the trial, participants will be entered into a prize draw to win one of 50, £20, gift vouchers.

Some participants will be invited to take part in an individual interview at the end of the study. This is optional.

 

This study closes on the 30th June 2025
 

Eating Disorders

EDGI is a project set up to explore risk factors in individuals who have experienced eating disorders, including anorexia nervosa, bulimia nervosa, binge-eating disorder or any other eating disorder at any time in their lives.

It aims to better understand the genetic and environmental links to eating disorders in order to improve treatments for current and future patients. EDGI is also part of the NIHR BioResource, which is a library of information about people’s health aiming to support research in both physical and mental health.

To take part in this study, people must:

  • Be aged 16 and above
  • Live in England
  • Be currently experiencing or have experienced an eating disorder

The EGDI study process involves of four steps:

  1. Registering on the website edgiuk.org and reading the information sheet
  2. Providing consent using the online form (please put AWP as where you heard about the study)
  3. Completing a questionnaire
  4. Providing a saliva sample

AWP Research and Development contact:

awp.edgi@nhs.net

 

This study will close on the 1st September 2024
 

 

General studies

The University of Bristol and Sheffield are interested in better understanding how to make mental health services work better together to improve mental health and reduce mental health inequalities. 

To take part in this study, people must: 

  • Be aged 18 years or above
  • For service users: Have accessed mental health services within Bristol or South Gloucestershire in the last 2 years
  • For staff: Have worked within mental health services within Bristol or South Gloucestershire 

Further Information:

Those who are interested will be invited to talk about their views of integrated health services in a group workshop, either in person at a venue in Bristol or online. This workshop will last approximately 2 hours.

Service users will be given £50 as a thank you for their time. For those who attend a face-to-face workshop, reasonable travel costs will be covered. 

Study contact:

Katrina d’Apice 
Email: katrina.dapice@bristol.ac.uk
Telephone: 0117 455 3759

 

This study will close on the 31st March 2024

Learning Disabilities

Art psychotherapy is used in the NHS to support people with mental health difficulties. However, more research is needed to find out if this therapy is helpful for people with learning disabilities in forensic and secure mental health services. 

The SCHEMA team are looking to find out if interpersonal art psychotherapy can reduce experiences of aggression for adults in secure care with borderline to mild/moderate learning disability. They also want to find out whether art psychotherapy can reduce the distress that these patients experience from their symptoms.  

To take part in this study, people must:

  • Be aged 18 to 60
  • Be an inpatient in an NHS secure hospital, unit, or service
  • Have a learning disability or borderline intellectual functioning
  • Be able to give informed consent
  • Have support from their responsible clinician or team to participate

Further information:

SCHEMA is a randomised control trial, which means a computer will randomly decide if participants receive art psychotherapy straight away or if they will be put on a waitlist for art psychotherapy. This means the researchers can compare art psychotherapy to usual care to see if it helps people. All participants will receive 12 weeks of art psychotherapy by the end of the study. 

Each art therapy session is an hour long, with one per week for a total of 12 sessions. In the sessions, individuals will be able to talk with a therapist and make artwork. They do not need to be good at art to do art therapy. Doing art during therapy can make it easier to communicate. 

Everyone who takes part in the study will be asked to complete some questionnaires with a researcher about their mental and physical health. These will be done at the start of the study, once after four months, and once more after nine months.

Individuals will receive a £15 voucher after the first questionnaire, a £15 voucher after the questionnaire at four months, and a final £20 voucher after the questionnaire at nine months, totalling £50 for completing the study.

AWP Research and Development contacts:

David Rudall (d.rudall@nhs.net)
Emily Avent (e.avent@nhs.net

You can also contact the study team by emailing schema@cardiff.ac.uk

This study will close on the 31st March 2024

SCHEMA logo.jpg
 

Perinatal 

The National Centre for Mental Health (NCMH) is heading an important research study called Maternal Wellbeing, Mental Health and Life Experiences.

This is an online survey that’s looking to understand more about how life experiences and COVID-19 have impacted on maternal wellbeing and mental health during the perinatal period.

We hope the findings will lead to new and improved ways of recognising and providing support in times of need.

The survey can be found here

To take part in this study, people must:

  • Be over 18-years-old
  • Be pregnant or have given birth in the last 12 months

Individuals with or without a mental health diagnosis are welcome to complete the survey.  

Participants will also be entered into a prize draw to win up to the value of £100 for their continued participation in the follow up maternal mental health surveys.

AWP Research and Development contacts:

Alexandra Young (alexandra.young6@nhs.net)  

 

This study closes on the 31st March 2025
 

Physical and mental health

The DIAMONDS Trial is a Randomised Control Trial (RCT) looking at improving diabetes self-management for people with severe mental illness (SMI) by comparing using a 6-month programme with usual care. 

The DIAMONDS trial aims to test a self-management intervention that can specifically help people with diabetes and severe mental illness to be healthier. The intervention has been developed in partnership with people with mental illness and diabetes, their family members/friends, and the healthcare staff who support them. 

The trial will last for 12 months. Taking part will involve completing a number questionnaires, clinical assessments, physical health checks and providing a blood sample at an initial appointment, and then again at 6 and 12 months. Visits will either take place at Gloucester Health and Care NHS Foundation Trust or Somerset Partnership NHS Trust. 

To take part in the study, people must:

  • Be aged 18 and over
  • Have a diagnosis of schizophrenia, bipolar disorder, schizoaffective disorder, psychosis or severe depression
  • Have a diagnosis of type 2 diabetes

DIAMONDS study team contact:

Dr Grace O'Carroll, Trial Coordinator  (Grace.ocarroll@york.ac.uk)

Lucy Sheehan, Trial Coordinator  (lucy.sheehan@york.ac.uk)

AWP Research and Development contact:

Monalisa Bora-White (monalisa.bora-white@nhs.net)

 

This study closes on 31st May 2024
 

Self-harm

Repeated self-harm is common, and is linked to other problems like lower quality of life and depression. The FReSH START RCT study team at the University of Leeds are running this study to see if adapted therapies are better at supporting people who self-harm, than therapies that are currently used in the NHS.

They have adapted three talking therapies that are currently used in the NHS. The study aims to see if these therapies improve quality of life and reduce self-damaging behaviours. 

To take part in this study, people must:

  • Have presented an Emergency Department (ED) for self-harm and have been assessed, as well as referred by the ED Team to the study
  • Be registered with a GP in the catchment area of Avon and Wiltshire Mental Health Partnership NHS Trust for the duration of therapy
  • Have mental capacity to provide fully informed consent
  • Be aged 18 years or over

People cannot take part in this study if they:

  • Are receiving, or been referred to, a specific psychological intervention that is similar to the trial intervention, or where a specific intervention is indicated for a related condition (e.g. anorexia nervosa) and would conflict with trial participation
  • Have taken part in the FReSH START Feasibility Study
  • Are assessed by a clinician as currently unsuitable for therapy. This may be due to individuals being in crisis, actively suicidal, past talking treatments leading to deterioration of mental state, diagnosis of schizophrenia, autism, or other severe mental illness that requires tailored talking therapies
  • Lack capacity to comply with study requirements
  • Have insufficient understanding of English to take part in talking therapy
  • Have a known risk of violence​​​​​​

 

Further information:

People who decide to take part will be allocated randomly (like tossing a coin) to either the intervention or the standard care. If they are allocated to intervention, they will then be allocated randomly again to either adapted Cognitive Behaviour Therapy or adapted Psychodynamic Interpersonal Therapy.

Participants who are randomly allocated to the intervention will have up to 12 sessions of therapy with a trained therapist. The sessions will take around 45 minutes each and will be done over a 6 month period. For people who are allocated to standard care, they will receive the care that the Trust normally provides to people who self-harm. Sessions can take place online or in person. 

During the study, monthly texts will be sent to participants to check in on how they are doing and whether they have self-harmed in the last month, these are secure and confidential texts. 

All participants will be asked to complete questionnaires at the start of the study, then at 6 months and 12 months into the study about wellbeing. There will also be some shorter questionnaires to complete at 3 months and 9 months into the study. 

Participants will get a £20 Amazon voucher for completing the questionnaires at 6 months from the start of the study, and a £40 Amazon voucher for completing the 12 month follow up questionnaires. 

 

AWP Research and Development contacts:

awp.freshstart.trial@nhs.net

 

This study closes on the 31st September 2024

 

FRESHSTART.png

Staff (internal and external)

The University of Manchester are conducting a research study to understand staff and service user views about using digital devices, such as a smartphone or wearable device, to help manage mental health. 

The study team would like to hear the opinions of healthcare professionals about this topic, as well as how digital health tools could be used in mental healthcare delivery.  

The study will aim to survey at least 300 healthcare professionals who provide care for those with psychosis, schizophrenia or any other mental health problem with psychotic experiences (for example hallucinations or delusions). The study team would like those taking part in the survey to have a wide range of experience using technology. This includes people that already use a smartphone or wearable device, and those that do not. 

To take part in this study, people must:

  • Be aged 18 or above
  • Be a healthcare professional who provides care for individuals diagnosed with psychosis, schizophrenia, or any other mental health issue which includes psychotic experiences (for example hallucinations or delusions)

Further information: 

You will be asked some questions about your age, occupation, and the service you work in. 

If you are able to take part, you will be asked to complete a survey; either online or using a paper copy. This survey will ask about your views of digital devices, as well as how these can be used in mental healthcare. 

The survey should take 20-30 minutes to complete. Survey responses are anonymous and there will be no way to identify the people that take part. 

By taking part in this survey, you service users are eligible to be entered into a prize draw to win £20 (as a voucher).

To read the participant information sheet and take part in the study, please click here

AWP Research and Development contacts: 

Harry Walker (harry.walker@nhs.net

 

This study closes on the 1st May 2024
 

Participant in Research Experience Survey (PRES)

Click the button below to tell us about your experience of taking part in research.